Cellectar Biosciences
CLRB
12 hedge funds and large institutions have $3.01M invested in Cellectar Biosciences in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
6.38% less ownership
Funds ownership: 22.41% → 16.03% (-6.4%)
14% less funds holding
Funds holding: 14 → 12 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
87% less capital inflows, than outflows
Capital inflows: $154K | Capital outflows: $1.23M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$117K |
| 2 |
JP Morgan Chase
New York
|
+$22.8K |
| 3 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$11.1K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$2.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
-$967K |
| 2 |
CVI Holdings
Wilmington,
Delaware
|
-$231K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$22K |
| 4 |
Morgan Stanley
New York
|
-$6.53K |
| 5 |
AIC
AWM Investment Company
New York
|
-$5K |
CLRB Hedge Fund Activity: Q3 2019 in Review
12 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q3 2019, worth a combined $3.01M — down 31% from $4.34M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CLRB and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $117K. The largest seller was Tang Capital Management, cutting an estimated $967K.
- 12 institutional investors held Cellectar Biosciences (CLRB) as of Q3 2019, down from 14 in Q2 2019.
- Funds reported $3.01M of Cellectar Biosciences stock for Q3 2019, down 31% quarter-over-quarter.
- 2 funds opened new Cellectar Biosciences positions in Q3 2019 and 4 closed out, a net change of -2 holders.
- The largest Cellectar Biosciences buyer in Q3 2019 was Renaissance Technologies, an estimated $117K added.
- The largest Cellectar Biosciences seller in Q3 2019 was Tang Capital Management, an estimated $967K sold.
Based on aggregated 13F filings for Q3 2019.